{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidytonmdpv35ckbh4cv6sptqps4qpq6i4zpqs6sjn55pouron5h7y",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mgg2f47suws2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreianthyuszyxv5grs2xfbagj3ap3ucc56dw7bzst7nd6zee6mrzeue"
    },
    "mimeType": "image/jpeg",
    "size": 97103
  },
  "path": "/news/2026-03-pet-imaging-reveals-ketamine-relieves.html",
  "publishedAt": "2026-03-06T13:00:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies. Although ketamine has emerged as a rapid-acting antidepressant for individuals with TRD, its underlying biological mechanism in the human brain has remained poorly understood, limiting efforts to optimize and personalize treatment.",
  "title": "PET imaging study reveals how ketamine relieves treatment-resistant depression"
}